

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 March 2024 (28.03.2024)



(10) International Publication Number
WO 2024/064178 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 25/16 (2006.01)
A61K 31/4375 (2006.01) A61P 25/24 (2006.01)
A61P 25/08 (2006.01) A61P 25/26 (2006.01)
A61P 25/14 (2006.01) A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2023/033206

(22) International Filing Date:

20 September 2023 (20.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/408,556 21 September 2022 (21.09.2022) US
63/426,421 18 November 2022 (18.11.2022) US

(71) Applicant: **NEUROCRINE BIOSCIENCES, INC.**
[US/US]; 12780 El Camino Real, San Diego, California
92130 (US).

(72) Inventors: **BOON, Byron, A.**; c/o Neurocrine Biosciences,
Inc., 12780 El Camino Real, San Diego, California 92130
(US). **PAGANO, Nicholas**; c/o Neurocrine Biosciences,
Inc., 12780 El Camino Real, San Diego, California 92130
(US). **HARRIOTT, Nicole**; c/o Neurocrine Biosciences,
Inc., 12780 El Camino Real, San Diego, California 92130
(US). **GU, Jieyu**; c/o Neurocrine Biosciences, Inc., 12780
El Camino Real, San Diego, California 92130 (US). **XUE,
Yibin**; c/o Neurocrine Biosciences, Inc., 12780 El Camino
Real, San Diego, California 92130 (US).

(74) Agent: **SEARS, Justin, Edward** et al.; Fish & Richardson
P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

WO 2024/064178 A1

(54) Title: **HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE**

(57) Abstract: This disclosure relates to, inter alia, certain compounds, compositions, and pharmaceutical compositions thereof, that modulate the activity of the transporter protein vesicular monoamine transporter-2 (VMAT2) and are directed to methods useful in the treatment of transporter protein vesicular monoamine transporter-2 mediated disorders, such as, neurological or psychiatric disease or disorders, including but not limited to, hyperkinetic movement disorders (e.g., tardive dyskinesia, Tourette's syndrome, Huntington's disease, tics, ataxia, chorea (such as, chorea associated with Huntington's disease), dystonia, hemifacial spasm, myoclonus, restless leg syndrome, and tremors). The disclosure further relates to synthetic methods and intermediates useful in the preparation of the compounds.